Clinical trials: BPH (Benign Prostatic Hyperplasia)
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
AVODART(Dutasteride) Post-marketing Surveillance(PMS)
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information
- Trial name
- AVO PMS (NCT01299571)
- Testing
- Dutasteride
- Where
- South Korea
- Volunteers
- 3,977 people
- Sponsor
- GlaxoSmithKline
Benign Prostate Hyperplasia
Pivotal Study to Assess the Safety and Effectiveness of the iTind Device
The study objectives are to demonstrate the efficacy and safety of the Medi-Tate iTIND as compared to control group (catheter only).
- Trial name
- NCT02506465
- Testing
- iTIND
- Where
- 13 sites in United States, Canada
- Volunteers
- 185 people
- Sponsor
- Medi-Tate Ltd.
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Deprescribing Tamsulosin in Older Men
This is a pilot 12-week randomized, placebo-controlled N-of-1 deprescribing trial among older men receiving chronic tamsulosin therapy for lower urinary tract symptoms attributed to benign prostatic hyperplasia.
- Trial name
- PERSONAL (NCT05415748)
- Testing
- Tamsulosin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of California, San Francisco
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary…
- Trial name
- NCT00710749
- Testing
- Disposable device, Digital device, Clinic flow measurement
- Where
- 4 sites in United States, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Wellspect HealthCare
Uterine Fibroid, Arteriovenous Malformations
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
This registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing HydroPearl embolization procedures via radial access.
- Conditions
- Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
- Trial name
- RAVI Registry (NCT04272216)
- Testing
- Treatment with HydroPearl via radial access
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Terumo Medical Corporation
Benign Prostatic Hypertrophy
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of…
- Trial name
- AEZS-102-Z041 (NCT00670306)
- Testing
- Cetrorelix Pamoate
- Where
- 69 sites in United States, Canada
- Volunteers
- 528 people
- Sponsor
- AEterna Zentaris
Benign Prostatic Hyperplasia
BPH-6: Comparison of the UroLift System to TURP for Benign Prostatic Hyperplasia
The purpose of this study is to compare the UroLift System Treatment to Transurethral Resection of the Prostate (TURP) in improving a patient's overall quality of life, while evaluating healthcare expenditures associated with…
- Trial name
- BPH-6 (NCT01533038)
- Testing
- UroLift System, Transurethral Resection of the Prostate
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- NeoTract, Inc.
Nonmalignant Neoplasm, Prostate Cancer
MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
RATIONALE: Diagnostic procedures, such as MRI and magnetic resonance spectroscopy imaging, may help in learning how well dutasteride works in patients with benign prostatic hypertrophy and low-risk prostate cancer.
- Trial name
- NCT00706966
- Testing
- dutasteride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Benign Prostatic Hyperplasia
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
This study will investigate the efficacy and safety of treatment with Dutasteride (0.5mg), administered once daily for one year in combination with Tamsulosin (0.4mg), administered once daily for 3 months, followed by counseling…
- Trial name
- NCT00701779
- Testing
- Tamsulosin
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Siami, Paul F., M.D.
Prostatic Hyperplasia
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.
A bio-equivalence of 2 different capsule formulations in fasted subjects
- Trial name
- NCT02417831
- Testing
- tamsulosin capsules, tamsulosin HCl
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
This retrospective study aims to assess the impact of early vs delayed 5-alpha-reductase inhibitor (5ARI) therapy in patients with BPH on alpha-blocker (AB) therapy and the risk of acute urinary retention (AUR), prostate-related…
- Trial name
- NCT01332487
- Testing
- 5ARI + AB
- Volunteers
- 4,068 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such…
- Trial name
- NCT00848081
- Testing
- Tadalafil
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 318 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Investigator-initiated study to evaluate the safety and efficacy of prostate artery embolization for the treatment lower urinary tract symptoms in patients with benign prostatic hyperplasia
- Trial name
- NCT03055624
- Testing
- Embosphere microparticles for prostate artery embolization
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Diego
Prostatic Hyperplasia
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and…
- Trial name
- NCT01323998
- Testing
- 5ARI, AB
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia (BPH)
Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
This is a Phase 4, prospective, open-label, randomized study of Greenlight XPS Laser versus BiVAP Saline Vaporization of the prostate in men with symptomatic Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT01500057
- Testing
- Greenlight XPS Laser, BiVAP Saline Vaporization of the prostate
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Brooklyn Urology Research Group
Prostatic Hyperplasia
A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)
This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.
- Trial name
- NCT01003886
- Testing
- Doxazosin mesylate GITS
- Where
- 67 sites in Philippines
- Volunteers
- 989 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Benign Prostatic Hyperplasia
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).
- Trial name
- NCT03297398
- Testing
- Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004)
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- OPKO Health, Inc.